Recruiting

Restylane Lyft with Lidocaine

Sponsor:

Galderma R&D

Code:

NCT07566286

Conditions

Chin Augmentation

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Accepted

Interventions

Restylane Lyft with Lidocaine

Study Details

Brief summary:

The primary objective of this study is to evaluate the safety of Restylane Lyft with Lidocaine for augmentation of the chin region 3 months after retreatment.

Conditions

Chin Augmentation

Study ID

NCT07566286

Start date

Jun 3, 2026

Status verified date

Aug, 2026

Completion date

Feb 28, 2028

Anticipated

Primary completion date

Nov 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Accepted

Inclusion Criteria:

1. Males or non-pregnant, non-breastfeeding females, 22 years of age or older.
2. Intent to receive treatment for augmentation and correction of retrusion in the chin region.

Exclusion Criteria:

1. Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel or to gram positive bacterial proteins.
2. Known/previous allergy or hypersensitivity to local anesthetics, e.g. lidocaine or other amide-type anesthetics.
3. Previous or present multiple allergies or severe allergies, such as manifested by anaphylaxis or angioedema, or family history of these conditions.
4. Previous facial surgery (including facial aesthetic surgery and liposuction), below the level of the horizontal line from subnasale.
5. Any previous aesthetic procedures or implants.
6. Presence of any disease or lesions near or on the area to be treated.

Study Design

Enrollment

100 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Dermal Filler for Indication: Restylane Lyft with Lidocaine

Participants will receive initial treatment with Restylane Lyft with Lidocaine in the chin region at Baseline with an optional touch-up treatment at 1 month after initial treatment and an optional retreatment 12 months after the last treatment.

Interventions

Restylane Lyft with Lidocaine

Sterile gel of hyaluronic acid.

Primary outcome measure

  • Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Related to Device And/Or Injection Procedure After the Month 12 Optional Retreatment [ Time Frame: From Month 12 up to 3 months after optional retreatment (i.e. Month 15) ]

Central Contacts and Locations

Central contacts

Locations

Galderma Investigational Site # 8680

Recruiting

Westport, Connecticut, United States, 06880

Galderma Investigational Site # 8774

Recruiting

Boynton Beach, Florida, United States, 33437

Galderma Investigational Site # 7030

Recruiting

Coral Gables, Florida, United States, 33134

Galderma Investigational Site # 8682

Recruiting

Coral Gables, Florida, United States, 33134

Galderma Investigational Site # 7042

Recruiting

Atlanta, Georgia, United States, 30331

Galderma Investigational Site # 7118

Recruiting

Nashville, Tennessee, United States, 37203

Galderma Investigational Site # 8662

Recruiting

Spring, Texas, United States, 77388

More Information

Sponsor

Galderma R&D

Last update posted

Aug 14, 2026

Last verified

Aug, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Galderma R&D on 2026-08-14.